Opinion

Video

CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC

5. Frank Scimeca, PharmD, MBA, BCOP, leads a discussion on sequencing CDK4/6 inhibitors, comparing their side effect profiles, toxicity benefits, and progression-free survival (PFS) advantages. He emphasizes the need for additional biomarkers and clearer guidance from the NCCN to aid in selecting the most appropriate drug for each patient.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
5 experts in this video
1 expert is featured in this series.
5 experts in this video
5 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Chemotherapy IV drip -- Image credit: sweetlemontea | stock.adobe.com
June 4th 2025

ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

Gillian McGovern, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Antibodies attacking cancer cell | Image Credit: © Anusorn - stock.adobe.com
June 2nd 2025

ASCO 2025: Expert Insights on Endocrine, Cardiac, Ocular, and Dermatologic Toxicities in Breast Cancer Care

Alexandra Gerlach, Associate Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
3D visualization of breast cancer cells | Image Credit: © Jack - stock.adobe.com
May 23rd 2025

APOBEC3 Mutagenesis May Drive Therapy Resistance in Patients With Breast Cancer

Alexandra Gerlach, Associate Editor
Woman with breast cancer awareness pink ribbon on her shirt -- Image credit: Siam | stock.adobe.com
May 21st 2025

Denosumab With Ovarian Function Suppression and Aromatase Inhibitor Therapy in ER-Positive, Early-Stage Breast Cancer

Grace Morrison, PharmD Candidate